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Abstract 
This study aims at quantifying and analyzing the online interest in the micropollutants Diclofenac and the Macrolide Antibiotics 
(Azithromycin, Clarithromycin and Erythromycin) included in the watchlist of the EU Decision 2015/495. Using online search traffic data 
from Google Trends, we examine the change in interest from 2004 to 2015 in five EU countries. The results show an increased Worldwide 
percentage change in interest in Diclofenac, Azithromycin and Clarithromycin over the selected period, in contrary to Erythromycin, that 
is declining. In the examined EU countries, Germany and the UK show the highest online interest with mostly increasing rates, while in 
France, Italy and Spain, the interest in all four substances is significantly lower.  
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1. Introduction 
According to Decision 2015/495/EU [1] issued on the 20th of March, 2015, the established watchlist for the EU 
monitoring of Environmental Quality Standards in the field of Water Policy consists of 17 substances; 17-Alpha-
ethinylestradiol, 17-Beta-estradiol Estrone, Diclofenac, 2,6-di-tetr-butyl-4-methylphenol, 2-ethylhexyl-4-
methoxycinnamate, Macrolide Antibiotics (consisting of Azithromycin, Clarithromycin and Erythromycin), 
Methiocrab, Neonicotinoids (consisting of Imidacloprid, Thiacloprid, Thimamethoxam, Clothianidin and 
Acetamiprid), Oxadiazon, and Triallate.  
Diclofenac, included in the EU watchlist and the 2nd most studied substance of the list over the course of the last 
ten years [2], is a non-steroidal anti-inflammatory and one of the most commonly used drugs [3], mostly as an 
analgesic, which is both orally and dermally administrated [4-5]. Diclofenac is not highly biodegradable [5] and not 
completely removed through biological wastewater treatment [2-3, 5-6]; in specific, Diclofenac’s removal in the 
wastewater treatment plants (WWTPs) varies from 0%-80% [6]. This results in its detection, in high frequencies [6], 
in WWTP effluents [7] and in the aqueous environment [3], i.e. surface water and groundwater [6], caused mainly 
through human and veterinary use [4]. Diclofenac is regarded to be harmful for environmental health [2], thus its 
concentrations in the water environment should be monitored in order to obtain water quality [3], even though there 
exist no legal limits for its discharge. 
The Macrolide Antibiotics, i.e. Azithromycin, Clarithromycin and Erythromycin, are antibacterial antibiotics [8] 
used for the treating and preventing of various infections [8-9] in humans, animals, and agriculture [8]. They have 
become the focus of attention, as bacteria can develop resistance to the antibiotics [8]. As the Macrolide Antibiotics 
cannot be fully degraded [9], they are detected in the aquatic environment: in wastewater, surface water and 
groundwater [8]. Even at low concentrations, they are viewed as possibly harmful to the environment [8], thus these 
substances require monitoring. 
The micropollutants’ impacts on the environment and human health need to be further evaluated [2]. Given the 
increasing scientific interest in micropollutants, and in order to explore the online interest in Diclofenac and the 
Macrolide Antibiotics included in the EU watchlist, large volumes of data and a wide variety of datasets are needed; 
namely Big Data. A popular tool to access these kinds of data is Google Trends [10], which is an open tool provided 
by Google that measures ‘What’s trending’. In general, online search traffic data has significant potential in improving 
forecastings [11] and in analyzing online interest [12]. Google Trends, as a tool for analyzing online behavior, has 
been highly integrated in academic research over the course of the last few years, with the validity of the Google 
Trends’ data [13] and its contribution to forecasting [14] being widely accepted and highlighted. If the terms are 
carefully selected, data from Google can be useful in accurately measuring various aspects of public interest [15].  
As Google Trends is becoming popular in scientific research, much focus is given in health related issues, with all 
the more studies integrating data from Google in their research. Previous work on the subject includes the detection 
of Tuberculosis outbreaks [16], the showing of the seasonality of the restless-legs symptoms [17], the examining of 
the change in online searches for Multiple Sclerosis [18], and the connections between online searches and dementia 
incidence [19]. Furthermore, Google Trends has been useful in examining the online changes in searches of keywords 
related to epilepsy [20] and in providing a quantitative analysis of epilepsy related searches [21]. Google Trends’ data 
have also been used to show that the online searches in Bariatric surgery are declining [22], to explore the online 
interest in cancer screening examinations in the US [23], and to examine searches related to skin diseases [24], snoring 
[25], lung cancer [26], tobacco use [27], and flu predictions [28] and spreading [29].  
As is suggested, Google Trends has the potential of becoming a valuable tool for the measurement of online interest, 
as it uses the revealed instead of the stated data [30], thus more accurately reflecting the public’s online behavior. Our 
aim is to look into online searches in Google, in order to examine and quantify at first the change in the Worldwide 
interest in Diclofenac, Azithromycin, Clarithromycin, Erythromycin, and then in the five most populated EU 
countries, i.e. Germany, France, UK, Italy and Spain, over the last 12 years. The rest of the paper is structured as 
follows: Section 2 consists of the research methodology used to evaluate the online interest, section 3 consists of the 
results and discussion, and section 4 consists of the overall conclusions and further research suggestions. 
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2. Methodology 
We use the Google Trends’ [10] normalized hits’ data from January 2004 to December 2015 to analyze the online interest 
in Diclofenac and the Macrolide Antibiotics, i.e. Azithromycin, Clarithromycin and Erythromycin, Worldwide and in the 5 
most populated countries in the EU: Germany, France, UK, Italy and Spain. Data are normalized over each selected period 
and are downloaded online in ‘*.csv’ format.  Let  ܦ௧೔, ܣ௧೔, ܥ௧೔, and ܧ௧೔ be the weekly hits of the downloaded Google 
Trends’ data for Diclofenac, Azithromycin, Clarithromycin, and Erythromycin of the i-th country, respectively. We 
define ܦ௧೛೔ , ܣ௧೛೔ , ܥ௧೛೔ , and ܧ௧೛೔  as the percentized weekly hits of their respective normalized Google searches, 
calculated using the equations: 
ܦ௧೛೔ ൌ
஽೟೔
஽೟೔ା஺೟೔ା஼೟೔ାா೟೔
          (1) 
 ܣ௧೛೔ ൌ
஺೟೔
஽೟೔ା஺೟೔ା஼೟೔ାா೟೔
           (2) 
ܥ௧೛೔ ൌ
஼೟೔
஽೟೔ା஺೟೔ା஼೟೔ାா೟೔
          (3) 
୲౦౟ ൌ
୉౪౟
ୈ౪౟ା୅౪౟ାେ౪౟ା୉౪౟
         (4) 
We proceed to calculate the yearly averages of the percentized hits and to analyze them in terms of change in 
interest from 2004 to 2015 in the four selected substances. The overall change from 2004 to 2015 is calculated by the 
formula (x2015-x2004)/x2004, where x denotes the respective yearly average of each region. We then perform a 
comparative analysis of Google searches Worldwide and the number of documents published in the Scopus database 
containing the terms "Diclofenac", "Azithromycin", "Clarithromycin" and "Erythromycin" in the field ‘Article title’. 
The selected documents include ‘Articles’, ‘Reviews’, ‘Letters’, ‘Notes’, and ‘Short Surveys’. 
3. Results and Discussion 
This section consists of the Worldwide and regional Google searches in Diclofenac, Azithromycin, Clarithromycin, and 
Erythromycin. The weekly hits are percentized and their yearly averages are further analyzed, in order to examine the change 
in online interest in the selected micropollutants, followed by a comparative analysis of the Scopus’ number of documents 
and Google Trends hits for the examined terms. 
3.1. Worldwide Interest 
Figure 1 shows the Worldwide hits in Google, and Table 1 consists of the yearly averages of the Worldwide percentized 
hits in the terms ‘Diclofenac’, ‘Azithromycin’, ‘Clarithromycin’, and ‘Erythromycin’ from January 2004 to December 2015. 
Based on Figure 1, we observe that the overall online interest is higher in the term Diclofenac, with Azithromycin, 
Erythromycin, and Clarithromycin following in that order from 2004 to 2015.  
Given the increased scientific interest in the substances and as they are suggested to be potentially harmful for 
environmental and human health, it would be expected that the public’s online interest could be increasing as well. 
According to the overall change in interest from 2004 to 2015, the Worldwide interest (Table 1) is highly increasing in 
Azithromycin, moderately increasing in Clarithromycin and Diclofenac, and shows a high decline in interest in the term 
‘Erythromycin’. 
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Fig 1. Worldwide hits in ‘Diclofenac’, ‘Azithromycin’, ‘Clarithromycin’ & ‘Erythromycin’ from 2004 to 2015 
Table 1. Yearly averages of the percentized Worldwide hits from 2004 to 2015. 
Year Diclofenac Azithromycin Clarithromycin Erythromycin 
2004 43.85 16.28 8.45 31.42 
2005 46.61 16.31 9.29 27.78 
2006 43.90 23.83 9.45 22.82 
2007 43.64 25.61 9.76 20.99 
2008 44.31 26.19 10.10 19.40 
2009 44.75 26.50 10.24 18.51 
2010 45.13 26.59 10.02 18.26 
2011 44.77 27.66 9.92 17.65 
2012 44.68 28.41 9.81 17.10 
2013 46.10 28.24 9.60 16.06 
2014 46.23 28.70 9.79 15.28 
2015 46.12 29.69 9.67 14.52 
Mean annual average 45.01 25.33 9.68 19.98 
3.2. Regional Interest 
Figure 2 consists of the normalized hits in the terms ‘Diclofenac’, ‘Azithromycin’, ‘Clarithromycin’, and ‘Erythromycin’, 
in Germany, France, United Kingdom, Italy, and Spain from January 2004 to December 2015. At first glance, it is quite 
evident that the online interest in all four substances is higher in Germany and the UK, while in France, Italy, and Spain the 
interest in the examined micropollutants is lower. 
Tables 2 and 3 consist of their yearly averages of the percentized hits from 2004 to 2015 in the five examined countries. 
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The normalized hits are percentized in order to further elaborate on the differences in online behavior towards the four 
substances. 
Table 2. Yearly averages of the percentized hits in ‘Diclofenac’ and ‘Azithromycn’ from 2004 to 2015 
 Diclofenac  Azithromycin 
Year Germany France UK Italy Spain  Germany France UK Italy Spain
2004 22.55 10.26 37.11 19.84 10.25  26.72 15.75 38.60 11.48 7.46 
2005 25.71 6.26 44.03 17.13 6.87  25.57 8.57 30.82 13.03 22.01 
2006 29.68 5.13 46.11 12.89 6.19  24.96 8.94 31.55 22.60 11.95 
2007 33.42 4.03 45.99 12.38 4.18  31.17 11.03 34.37 14.09 9.34 
2008 36.53 4.55 42.27 11.81 4.84  32.98 7.08 36.54 12.22 11.17 
2009 35.95 5.17 42.07 11.72 5.09  36.28 6.28 37.43 10.59 9.43 
2010 35.24 6.24 41.70 11.28 5.54  37.15 5.94 40.60 7.90 8.41 
2011 36.89 6.71 43.02 10.80 2.58  41.42 4.08 43.39 5.00 6.11 
2012 39.13 8.22 38.86 11.36 2.43  43.74 4.15 43.18 3.83 5.10 
2013 40.89 9.98 34.18 12.48 2.47  45.47 3.68 42.38 3.48 5.00 
2014 44.03 11.09 27.36 14.64 2.86  46.02 3.79 43.01 2.97 4.21 
2015 45.14 12.51 23.90 15.58 2.88  48.03 3.30 42.12 2.66 3.88 
% Change 100.15 21.92 -35.59 -21.47 -71.90  79.78 -79.03 9.13 -76.80 -47.99 
Based on the calculated yearly averages of the normalized hits in Diclofenac, high online interest is observed in Germany 
and the UK, which is increasing and declining, respectively. Italy shows a moderate interest in the term that is decreasing, 
while France and Spain achieve the lowest interest, with Spain’s interest decreasing from 2004 to 2015.  
  
(a) (b) 
  
(c) (d) 
Fig. 2. Normalized hits in Germany, France, UK, Italy and Spain (a) Diclofenac; (b) Azithromycin; (c) Clarithromycin ; (d) Erythromycin for 
2004-2015.  
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For the Macrolide Antibiotics, the interest in Azithromycin in the five selected countries is as follows: Germany and the 
UK show high online interest, while France, Italy and Spain show much lower interest. In Clarithromycin, high interest is 
observed in the UK and Germany, while low interest in the term is observed in France, Italy and Spain. In Erythromycin, 
UK and Germany show high interest, while France, Italy, and Spain show lower interest. 
Table 3. Yearly averages of the percentized hits in ‘Clarithromycin’ and ‘Erythromycin’ from 2004 to 2015 
 Clarithromycin  Erythromycin 
Year Germany France UK Italy Spain  Germany France UK Italy Spain
2004 33.28 5.69 44.15 15.19 1.69  20.11 9.20 49.22 13.20 8.27 
2005 42.10 4.80 43.37 6.64 3.09  19.69 6.74 52.70 11.16 9.71 
2006 35.58 8.54 38.58 6.59 10.70  20.41 5.45 57.96 6.59 9.59 
2007 36.67 5.31 39.58 9.84 8.60  21.71 4.69 61.32 7.45 4.83 
2008 37.43 7.57 38.33 11.41 5.27  24.61 3.47 60.50 5.55 5.86 
2009 36.42 6.23 41.07 8.44 7.85  26.05 3.79 59.66 5.73 4.75 
2010 36.49 3.51 46.62 6.34 7.04  28.41 2.90 59.77 4.34 4.59 
2011 34.95 3.11 53.73 4.09 4.12  25.28 1.73 67.84 2.29 2.86 
2012 31.12 2.63 60.21 3.00 3.05  30.13 1.74 63.67 2.09 2.37 
2013 31.19 2.22 60.91 2.56 3.12  31.12 1.83 63.75 1.51 1.80 
2014 26.41 1.90 66.88 2.15 2.67  30.02 1.51 64.53 1.49 2.45 
2015 26.88 1.53 67.38 1.70 2.52  31.35 1.82 63.37 1.74 1.72 
% Change -19.23 -73.16 52.60 -88.79 48.90  55.91 -80.27 28.75 -86.78 -79.19 
The percentages in the regional change in interest over the examined period is as follows: Diclofenac’s online interest is 
increasing in Germany (100.15%) and France (21.92%), and is significantly decreasing in the UK (-35.59%), Italy (-21.47%) 
and Spain (-71.90%). In Azithromycin, Germany’s (79.78%) and UK’s (9.13%) interest in the term are increasing, while 
France (-79.03%), Italy (-76.80%) and Spain (-47.99%) show a high decrease. In Clarithromycin, the only country with an 
increased online interest is the UK (52.60%) –Spain’s high increase in percentage difference is due to an increase from 
1.69% to 2.52%. Finally, the interest in the term Erythromycin is increasing in Germany (55.91%) and the UK (28.75%), 
with France (-80.27%), Italy (-86.78%) and Spain (-79.19%) showing a significantly high decrease. 
3.3. Research publications for the examined substances 
Over the course of the last 12 years, several studies have been dedicated to examining the micropollutants’ occurrence 
and removal [2] and their impact on the environment and human health. Directive 2000/60/EC is the first one related to 
Water Policy in the EU, opening the discussion of defining and prioritizing high risk substances [31], followed by 
Directive 2008/105/EC that approved 33 priority substances and their Environmental Quality Standards [32]. 
Directive 2013/39/EU [33] proposed a list of 45 priority substances, in addition to recommending Diclofenac, 17-
Alpha-ethinylestradiol (EE2) and 17-Beta-Estradiol (E2) in the list of substances for monitoring, which was later 
implemented in Decision 2015/495 [1]. The most studied substances out of the ones consisting the list for monitoring are 
Diclofenac, the Macrolide Antibiotics (Azithromycin, Clarithromycin and Erythromycin), EE2, E2 and Estrone (E1), 
while for the rest of the list’s substances [1] not enough research has been documented yet [2].  
Table 4 consists of the last twelve years’ Scopus’ number of documents with Diclofenac, Macrolide Antibiotics, 
Azithromycin, Clarithromycin & Erythromycin in the title  [34], and Figure 3 of the relative interest among the four 
substances for Google Trends and published papers. 
Further statistical analysis, as shown in Figure 3 and Table 4, suggest that the number of scientific publications for each 
term is related to the terms’ rankings in online interest, i.e. Diclofenac, Azithromycin, Clarithromycin, and Erythromycin in 
that order.  
However, for Diclofenac the share of the public interest among the four substances in Google Trends is higher compared 
to Scopus (Z=2.7376, p<0.01), while for Clarithromycin the share of the public interest among the four substances in Google 
Trends is lower compared to Scopus (Z=-5.5878, p<0.001). 
Table 4. Scopus published documents with the four substances in their title from 2004 to 2015 
Year Diclofenac Azithromycin Clarithromycin Erythromycin 
2004 176 119 118 127 
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2005 172 149 104 142 
2006 177 92 93 118 
2007 178 143 89 134 
2008 204 115 98 121 
2009 238 120 110 110 
2010 249 116 97 95 
2011 279 153 101 114 
2012 270 153 108 80 
2013 286 179 135 97 
2014 296 202 123 95 
2015 254 152 91 79 
Total 2779 1693 1267 1312 
Percentage share 39.41% 24.01% 17.97% 18.61% 
 
 
Fig. 3. Relative interest among the four substances for GoȠgle ȉrends and published papers in Scopus 
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4. Conclusions 
This aim of this study was to quantify and analyze the online interest in Diclofenac and the Macrolide Antibiotics, i.e. 
Azithromycin, Clarithromycin, and Erythromycin, substances included in the watchlist of the EU Decision 2015/495. We 
used normalized data from Google Trends in order to examine the change in interest from 2004 to 2015 in Germany, France, 
UK, Italy and Spain. Quantifying the hits by percentizing the normalized weekly data, we observed an increased Worldwide 
interest in Diclofenac and Azithromycin, stable interest in Clarithromycin, and a high decrease in Erythromycin. In specific, 
the regional interest in Germany and UK is higher in all terms, and, in most cases, increasing, compared to France, Italy, 
and Spain. The percentage differences show that in Germany the interest in all substances except for Clarithromycin is 
increasing, and in the UK the interest in Diclofenac is decreasing, while searches in the Macrolide Antibiotics are increasing. 
In France the overall interest in all substances apart from Diclofenac is significantly decreasing, the same as in Italy and 
Spain, where the interest in all terms is significantly decreasing. In addition, both the scientific community (in terms of 
published papers) and the public are interested on the examined substances in the same order, i.e. Diclofenac, Azithromycin, 
Clarithromycin, and Erythromycin.  
Google Trends is suggested to be a valid tool for evaluating online interest, as it uses the public’s revealed and not the 
stated preferences. Data from Google Trends have been used in a high number of studies in health related issues, aiming at 
examining the overall increases or declines in interest in several medical terms. Further research on the subject could include 
the exploring of the online interest in all EU countries, in addition to the examining of the countries’ interest in relation to 
their GDP per capita and their respective Health Care Systems’ performance.  
References 
[1] http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=uriserv:OJ.L_.2015.078.01.0040.01.ENG (accessed on April 29, 2016). 
[2] M.O. Barbosa, N.F.F. Moreira, A.R. Ribeiro, M.F.R. Pereira, A.M.T. Silva, Occurrence and removal of organic micropollutants: An overview of the 
watch list of EU Decision 2015/495, Water Res. 94 (2016) 257–279. 
[3] M. Huebner, E. Weber, R. Niessner, S. Boujday, D. Knopp, Rapid analysis of diclofenac in freshwater and wastewater by a monoclonal 
antibody-based highly sensitive ELISA, Anal. Bioanal. Chem. 407:29 (2015) 8873–8882.  
[4] D. Stülten, S. Zühlke, M. Lamshöft, M. Spiteller, Occurrence of diclofenac and selected metabolites in sewage effluents, Sci. Tot. Environ. 
405:1–3 (2008) 310–316. 
[5] N. Vieno, M. Sillanpää, Fate of diclofenac in municipal wastewater treatment plant - A review, Environ. Int. 69 (2014) 28–39. 
[6] Y. Zhang, S.U. Geißen, C. Gal, Carbamazepine and diclofenac: Removal in wastewater treatment plants and occurrence in water bodies, 
Chemosphere 73:8 (2008) 1151–1161. 
[7] P. Schröder, B. Helmreich, B. Škrbiü, M. Carballa, M. Papa, C. Pastore, Z. Emre, A. Oehmen, A. Langenhoff, M. Molinos, J. Dvarioniene, C. 
Huber, K.P. Tsagarakis, E. Martinez-Lopez, S.M. Pagano, C. Vogelsang, G. Mascolo, Status of hormones and painkillers in wastewater effluents 
across several European states—considerations for the EU watch list concerning estradiols and diclofenac, Environ. Sci. Pollut. Res. 23:13 
(2016) 12835–12866. 
[8] N.P. Xekoukoulotakis, N. Xinidis, M. Chroni, D. Mantzavinos, D. Venieri, E. Hapeshi, D. Fatta-Kassinos, UV-A/TiO2 photocatalytic 
decomposition of erythromycin in water: Factors affecting mineralization and antibiotic activity, Catal. Today. 151:1–2 (2010) 29–33. 
[9] F. Lange, S. Cornelissen, D. Kubac, M.M. Sein, J. von Sonntag, C.B. Hannich, A. Golloch, H.J. Heipieper, M. Möder, C. von Sonntag, 
Degradation of macrolide antibiotics by ozone: A mechanistic case study with clarithromycin, Chemosphere 65:1 (2006) 17–23. 
[10] www.google.com/trends (accessed on April 25, 2016). 
[11] S.P. Jun, D.H. Park, J. Yeom, The possibility of using search traffic information to explore consumer product attitudes and forecast consumer 
preference, Technol. Forecast. Soc. 86 (2014) 237–253. 
[12] S.P. Jun, D.H. Park, Consumer information search behavior and purchasing decisions: Empirical evidence from Korea, Technol. Forecast. 
Soc. 107 (2016) 97–111. 
[13] M.L. McCallum, G.W. Bury, Public interest in the environment is falling: a response to Ficetola (2013), Biodivers. Conserv. 23:4 (2014) 
1057–1062. 
[14] S. Vosen, T. Schmidt, Forecasting private consumption: Survey-based indicators vs. Google trends, J. Forecasting. 30:6 (2011) 565–578. 
[15] M. Scharkow, J. Vogelgesang, Measuring the public agenda using search engine queries, Int. J. Public Opin. Res. 23:1 (2011) 104–113. 
[16] X. Zhou, J. Ye, Y. Feng, Tuberculosis surveillance by analyzing google trends, IEEE Trans. Biomed. Eng. 58:8 (2011) 2247–2254.  
[17] D.G. Ingram, C.K. Matthews, D.T. Plante, Seasonal trends in sleep-disordered breathing: evidence from Internet search engine query, Sleep 
Breath. 19:1 (2014) 79–84. 
[18] F. Brigo, P. Lochner, F. Tezzon, R. Nardone, Web search behavior for multiple sclerosis: An infodemiological study, Mult. Scler. Relat. 
Disord. 3:4 (2015) 440–443. 
[19] H.W. Wang, D.R. Chen, H.W. Yu, Y.M. Chen, Forecasting the incidence of dementia and dementia-related outpatient visits with google 
trends: Evidence from Taiwan, J. Med. Internet Res. 17:11 (2015) e264. 
584   Amaryllis Mavragani et al. /  Procedia Engineering  162 ( 2016 )  576 – 584 
[20] F. Brigo, S.C. Igwe, H. Ausserer, R. Nardone, F. Tezzon, L.G. Bongiovanni, E. Trinka, Why do people google epilepsy? An infodemiological 
study of online behavior for epilepsy-related search terms, Epilepsy and Behav. 31 (2014) 67–70. 
[21] N.L. Bragazzi, S. Bacigaluppi, C. Robba, R. Nardone, E. Trinka, F. Brigo, Infodemiology of status epilepticus: A systematic validation of the 
Google Trends-based search queries, Epilepsy Behav. 55 (2016) 120–123. 
[22] F. Linkov, D.H. Bovbjerg, K.E. Freese, R. Ramanathan, G.M. Eid, W. Gourash, Bariatric surgery interest around the world: What Google 
Trends can teach us, Surg. Obes. Relat. Dis. 10:3 (2014) 533–538. 
[23] A.B. Rosenkrantz, V. Prabhu, Public interest in imaging-based cancer screening examinations in the United States: Analysis using a web-
based search tool, Am. J. Roentgenol. 206:1 (2016) 113–118. 
[24] J. Whitsitt, C. Karimkhani, L.N. Boyers, J.P. Lott, R.P. Dellavalle, Comparing burden of dermatologic disease to search interest on google 
trends, Dermatol. Online J. 21:1 (2015) 
[25] D.G. Ingram, D.T. Plante, Seasonal trends in restless legs symptomatology: Evidence from Internet search query data, Sleep Med. 14:12 (2013) 
1364–1368. 
[26] Z. Zhang, X. Zheng, D.D. Zeng, S.J. Leischow, Information seeking regarding tobacco and lung cancer: Effects of seasonality, PLoS ONE. 
10:3 (2015) e0117938. 
[27] P.A. Cavazos-Rehg, M.J. Krauss, E.L. Spitznagel, A. Lowery, R.A. Grucza, F.J. Chaloupka, L.J. Bierut, Monitoring of non-cigarette tobacco 
use using google trends, Tob. Control. 24:3 (2015) 249–255. 
[28] M.W. Davidson, D.A. Haim, J.M. Radin, Using networks to combine ‘Big Data’ and traditional surveillance to improve influenza predictions, 
Sci. Rep. 5 (2015) 8154. 
[29] V. Dukic, H.F. Lopes, N.G. Polson, Tracking epidemics with Google Flu trends data and a state-space SEIR model, J. Am. Stat. Assoc. 170:500 
(2012) 1410–1426. 
[30] A. Mavragani, K.P. Tsagarakis, YES or NO: Predicting the 2015 Greferendum results using Google Trends, Technol. Forecast. Soc. Change. 
109 (2016) 1–5. 
[31] http://ec.europa.eu/health/endocrine_disruptors/docs/wfd_200060ec_directive_en.pdf (accessed on May 2, 2016). 
[32] http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:348:0084:0097:en:PDF (accessed on May 2, 2016). 
[33] http://data.europa.eu/eli/dir/2013/39/oj (accessed on May 2, 2016). 
[34] www.scopus.com (accessed on August 12, 2016). 
